Keros Therapeutics IPO

4/7/2020

IPO

$96,000,000

Per the firm's most recent regulatory filing, it plans to use the net proceeds as follows: approximately $8.1 million to advance the clinical development of KER-050, including the initiation of two Phase 2 clinical trials, one in patients with MDS and one in patients with myelofibrosis; approximately $13.1 million to advance the clinical development of KER-047, including the completion of our current Phase 1 clinical trial and the initiation of two Phase 2 clinical trials, one in patients with IRIDA and anemias with elevated hepcidin, including myelofibrosis, and one in patients with FOP; approximately $5.3 million to advance KER-012 into clinical development, including the initiation of a Phase 1 clinical trial; and the remainder to fund other research and development activities, including activities related to our proprietary discovery approach, working capital and general corporate purposes.

Publicly-held

Biopharmaceutical

99 Hayden Ave. Building E 120
Lexington, MA 02421
USA

Not Recorded

Keros Therapeutics (Nasdaq: KROS) harnesses the knowledge of leading physician researchers and medical experts in the discovery and development of novel proprietary therapeutics for neuromuscular diseases. Headquartered in Lexington, Massachusetts, Keros Therapeutics is led by President and CEO Dr. Jasbir Seehra, who has over three decades of hands-on experience creating first-tier drug therapies.